Validation of a Novel Screening Test for Maternal Insulin Resistance
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03388697 |
|
Recruitment Status :
Recruiting
First Posted : January 3, 2018
Last Update Posted : January 3, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This will be a validation study of Quantose IR and Quantose IGT to predict insulin resistance and identify patients with prediabetes. This is a pilot study of 100 subjects. Based on the results of this initial trial, investigators plan to perform a larger trial at UTMB.
Quantose IR is a fasting blood test for insulin resistance and prediabetes, and is clinically validated in non-pregnant individuals. The Quantose IR Score is based on three novel nonglycemic biomarkers, as well as insulin, and provides a comprehensive measure of insulin resistance. These analytes include:
- α-HB (α-hydroxybutyrate): positively correlated with insulin resistance and indicative of early β-cell dysfunction.
- L-GPC (linoleoyl-glycerophosphocholine): negatively correlated with insulin resistance and impaired glucose tolerance.
- Oleic Acid: positively correlated with increasing lipolysis and insulin resistance.
- Insulin: increased insulin is characteristic of insulin resistance and is an independent risk factor for type 2 diabetes and cardiovascular disease.
Quantose IGT is designed to estimate the risk of being IGT. It is calculated from a multiple logistic regression model based on the fasting plasma levels of:
- Glucose.
- α−HB.
- β−HB.
- 4-methyl-2-oxopentanoic acid.
- LGPC.
- Oleic acid.
- Serine.
- Vitamin B5. Participants in the study will be consenting to data collection and two visits for lab draw. The investigators will then evaluate the performance of the Quantose IR and Quantose IGT in the study population.
| Condition or disease | Intervention/treatment |
|---|---|
| Insulin Resistance, Diabetes | Diagnostic Test: Quantose IR and Quantose IGT analysis Diagnostic Test: HOMA IR the standard testing for insulin resistance |
This is a prospective cohort non-interventional study. Subjects will be identified during the time of a prenatal visit at one of the UTMB clinics. All necessary institutional and regulatory approval will be obtained prior to enrolling any candidates for this study.
Potential subjects that are not patients of the investigator or patients of the study team members, they will not be contacted by study staff unless they have been informed of the study by their medical provider and express an interest in receiving more information on the study or wish to enroll in the study. Under the direction of the PI, trained research staff will be available in the UTMB prenatal care clinics to screen and consent subjects according to study protocol. The Perinatal Research Division (PRD) has staff based in the UTMB Maternal Health (OB) clinics. These research staff members will screen the charts and electronic medical records of prenatal patients receiving care in the OB clinics. In order to contact potential study participants, the HIPAA waiver is submitted.
In addition, the OB clinic staff will be in serviced on the study and encouraged to refer potential subjects to the PRD staff. Other than the blood samples for this study, the management of pregnancy and delivery will be according to the standard of care at UTMB and will be up to the clinical provider.
Blood samples will be collected during 2 windows, early window (gestational age 10 0/7 to 13 6/7 weeks) and late window (gestational age 24 0/7 to 28 0/7 weeks) and stored at -800C in our perinatal research division. An aliquot will be sent to Metabolon to run the Quantose IR and Quantose IGT. The laboratory and the investigators will be blinded to the outcomes of the patient.
Testing using Quantose IR and Quantose IGT: The blood draws will be timed to coincide with clinically indicated blood tests as much as possible (e.g. first visit labs, aneuploidy screening, gestational diabetes screening).
Testing using HOMA IR: The investigators will be measuring fasting insulin and glucose levels (last meal more than 8hrs before testing i.e. overnight fasting) from EDTA-plasma samples. After collection, the samples will be spun and plasma obtained. Samples will be stored until testing.
Two tubes (total = 20cc) of blood will be collected from participants who will be asked to fast for minimum of 8 hours prior to blood draw.
The samples from both time points will be sent together to Metabolon for Quantose IR and Quantose IGT analysis.
| Study Type : | Observational |
| Estimated Enrollment : | 100 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Validation of a Novel Screening Test for Maternal Insulin Resistance and Predicting Maternal Fetal Outcomes: A Pilot Study. |
| Actual Study Start Date : | December 15, 2017 |
| Estimated Primary Completion Date : | December 15, 2019 |
| Estimated Study Completion Date : | December 15, 2019 |
- Diagnostic Test: Quantose IR and Quantose IGT analysis
Testing using Quantose IR and Quantose IGT: The blood draws will be timed to coincide with clinically indicated blood tests as much as possible (e.g. first visit labs, aneuploidy screening, gestational diabetes screening).Other Name: QUANTOSE® IR, QUANTOSE® IGTT
- Diagnostic Test: HOMA IR the standard testing for insulin resistance
Testing using HOMA IR: Investigators will be measuring fasting insulin and glucose levels (last meal more than 8hrs before testing i.e. overnight fasting) from EDTA-plasma samples. After collection, the samples will be spun and plasma obtained. Samples will be stored until testing. The investigators will be using the following computation to calculate HOMA.Other Name: HOMA IR
- Gestational Diabetes [ Time Frame: Up to 28 0/7 weeks of gestation ]Development of gestational diabetes (based on the two step approach: 1hr glucose screen > 135mg/dL and 2/4 abnormal values in a 3 hr OGTT using the Carpenter and Coustan
- Insulin resistance [ Time Frame: Up to 28 0/7 weeks of gestation ]Defined as abnormal HOMA IR
- Fasting Plasma glucose [ Time Frame: Up to 28 0/7 weeks of gestation ]Measuring plasma glucose
- Fasting Insulin [ Time Frame: Up to 28 0/7 weeks of gestation ]Measuring plasma insulin level
- 1 hour glucola [ Time Frame: Up to 28 0/7 weeks of gestation ]after receiving 50grams glucose load po and plasma glucose level is drawn 1 hour later
- Perinatal death [ Time Frame: up to 7 days after delivery ]stillbirths plus early neonatal deaths (under 7 days)
- Neonatal hypoglycemia [ Time Frame: up to 7 days after delivery ]Neonate plasma glucose < 90mg/dL
- NICU admission [ Time Frame: up to 7 days after delivery ]Admission to the neonatal intensive care unit
Biospecimen Retention: Samples Without DNA
Two tubes (total = 20cc) of blood will be collected from participants who will be asked to fast for minimum of 8 hours prior to blood draw.
The samples from both time points will be sent together to Metabolon for Quantose IR and Quantose IGT analysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Pregnant women |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
- Known or suspected fetal anomaly.
- Pre-gestational diabetes.
- Pre-pregnancy hypertension.
- Receiving medication that would interfere with Quantose IR or would increase IR (e.g. steroids).
- Prisoners.
Inclusion Criteria:
- 18 years or older.
- Singleton pregnancy.
- Able to provide consent.
- Gestational age 10 0/7 to 13 6/7 weeks.
- Planned delivery at UTMB (John Sealy Hospital (JSH) or League City Hospital Campus.
- Pre-pregnancy or early pregnancy BMI >35 kg/m2
Exclusion Criteria:
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03388697
| Contact: Antonio Saad, MD | 409 7772 0982 | afsaad@utmb.edu | |
| Contact: Ashley Salazar | 409 772 0312 | assalaza@utmb.edu |
| United States, Texas | |
| Ashley Salazar | Recruiting |
| Galveston, Texas, United States, 77555 | |
| Contact: Antonio Saad, MD 409-772-0982 afsaad@utmb.edu | |
| Contact: Ashley Salazar 140927720312 assalaza@utmb.edu | |
| Principal Investigator: Antonio Saad, MD | |
| Sub-Investigator: George Saade, MD | |
| Principal Investigator: | Antonio Saad, MD | UTMB Galveston |
Publications:
| Responsible Party: | The University of Texas Medical Branch, Galveston |
| ClinicalTrials.gov Identifier: | NCT03388697 History of Changes |
| Other Study ID Numbers: |
17-0228 |
| First Posted: | January 3, 2018 Key Record Dates |
| Last Update Posted: | January 3, 2018 |
| Last Verified: | December 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Additional relevant MeSH terms:
|
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
Insulin, Globin Zinc Insulin Hypoglycemic Agents Physiological Effects of Drugs |